Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Saronno – page 167

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Saronno at a glance
2 862
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 862 trials in Saronno

Open in trial search

Non-small cell lung cancer

Not recruiting

Study on the Effect of Cemiplimab in Patients with Oligometastatic Non-Small Cell Lung Cancer After Radical Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Prostate cancer

Not recruiting

Study of Pembrolizumab and 68GA-PSMA HBED-CC in Patients with High-Risk Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Ospedale San Raffaele S.r.l.

Colorectal cancer metastatic

Not recruiting

Study Comparing Sotorasib and Panitumumab with Other Drug Combinations for Patients with Metastatic Colorectal Cancer and KRAS p.G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Amgen Inc.

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Desmoid tumour

Not recruiting

Study of varegacestat (AL102) in patients with progressing desmoid tumors

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Varegacestat
  • Sponsor:Immunome Inc.

Richter's syndrome

Not recruiting

Study on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Triple negative breast cancer

Not recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Inguinal hernia+1

Not recruiting

Study on the Effectiveness and Safety of Chloroprocaine Hydrochloride for Children Undergoing Flat Foot or Inguinal Hernia Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Codeine Phosphate
  • Sponsor:Sintetica S.A.

Triple negative breast cancer

Not recruiting

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer+2

Not recruiting

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Patients with Colorectal, Biliary Tract, and Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

  • MET deregulation therapy assessment
  • Second-line combination treatments
  • EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

  • Endocrine-responsive breast cancer treatment
  • Ovarian cancer maintenance therapy
  • BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

  • Metastatic renal cancer therapy
  • Atrial fibrillation management
  • Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.